Targetable pathways in the treatment of retroperitoneal liposarcoma

HIGHLIGHTS

• who: Lucia Casadei and colleagues from the (UNIVERSITY) have published the research work: Targetable Pathways in the Treatment of Retroperitoneal Liposarcoma, in the Journal: Cancers 2022, 14, 1362. of /2022/
• how: This review discusses the current treatments under evaluation for and the potential targetable pathways in Grignol V. Targetable Pathways in the Treatment of
• future: Based on these reports DDLPS patients may benefit from immune checkpoint inhibitor therapy though further study is certainly needed . And Future Directions Since RPLPS therapies based on the most common dysregulated molecular pathways have not demonstrated adequate treatment . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.